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Abstract 
In the last couple of decades, breast conservation therapy, which utilizes a combination of surgery, radiother-
apy, and endocrine or chemotherapy, has become the standard of care for treating early-stage breast cancer. 
This practice has been greatly beneficial in the improvement of the patient’s quality of life but has also led to 
the increased use of radiotherapy and associated soft-tissue sarcomas, with angiosarcoma being the most 
common malignancy. Radiation-associated angiosarcoma (RAS) of the breast is a rare phenomenon, which 
has been reported to occur in approximately 0.9 out of 1,000 cases, with a reported onset as late as 23 years 
following radiotherapy. Here we report 2 cases of RAS that occurred within 6 and 13 years following radio-
therapy of their primary breast lesion. We discuss the diagnostic and therapeutic challenges regarding this 
disease and review the current literature. This case report serves as cautionary lessons on the importance of 
considering RAS of the breast in the differential diagnosis during evaluation for recurrent breast neoplasms. 
Ongoing clinical trials using combinations of vascular endothelial growth factor inhibitors and chemotherapy 
may provide future avenues of treatment for this difficult-to-treat disease. 
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In the last 20 years, breast conservation therapy, which utilizes a combination of sur-
gery, radiotherapy, and endocrine or chemotherapy, has become the standard of care for 
treating early-stage breast cancer. This practice has been greatly beneficial in the improve-
ment of the patient’s quality of life but has also led to the increased use of radiotherapy. Un-
fortunately, this has also led to a reported increase in radiotherapy-associated soft-tissue 
sarcomas, with angiosarcoma being the most common malignancy [1, 2]. Radiation-
associated angiosarcoma (RAS) of the breast is a rare phenomenon, which has been reported 
to occur in approximately 0.9 out of 1,000 cases, with a reported onset as late as 23 years 
following radiotherapy [1–5]. Here we report 2 cases of RAS that occurred within 6 and 13 
years following radiotherapy of their primary breast lesion. We discuss the diagnostic and 
therapeutic challenges regarding this disease and review the current literature. This case 
report serves as cautionary lessons on the importance of considering RAS of the breast in the 
differential diagnosis during evaluation for recurrent breast neoplasms. 
Case Report 
Case 1 
A 68-year-old female was diagnosed with stage II (T1N1M0) invasive ductal carcinoma, 
which was estrogen receptor (ER) and progesterone receptor (PR) positive. She was treated 
with a right breast partial mastectomy followed by adjuvant radiotherapy and 5 years of 
endocrine therapy with an aromatase inhibitor as the patient refused chemotherapy. Six 
years after initial diagnosis, the patient developed multiple red papules on the inferior por-
tion of her right breast with an initial biopsy showing atypical postradiation cells. Due to 
concern for possible recurrence of her breast cancer (especially since she had refused adju-
vant chemotherapy), a bilateral mastectomy was performed. To our surprise, the surgical 
pathology results showed low-grade multifocal angiosarcoma centered in the dermis and 
extending up to 1.1 cm, with multiple nodules of vascular proliferation throughout the der-
mis and perineural invasion and focal infiltration into the subdermal adipose tissue (Fig. 1a). 
Two months after mastectomy, a follow-up positron emission tomography and computed 
tomography scan showed no evidence of residual or active hypermetabolic foci indicative of 
metastatic disease. After a long discussion with the patient, a decision was made for close 
surveillance as her poor performance status and multiple medical comorbidities made her 
an inadequate candidate for adjuvant chemotherapy with various anthracyclines or vascular 
endothelial growth factor (VEGF) inhibitors.  
Case 2 
A 44-year-old female was diagnosed with stage II (T1N1M0) invasive ductal carcinoma 
of the left breast, which was ER/PR negative. She was treated with neoadjuvant chemother-
apy, which was followed by left breast mastectomy, sentinel lymph node dissection, and 
adjuvant radiotherapy. On surgical pathology, the patient had complete response with only 
residual ER/PR-negative ductal carcinoma in situ with no residual nodal disease. Of note, 
genetic testing for BRCA1 and 2 genes did not show any known driver mutations but did 
show some single nucleotide polymorphisms which were consistent with variation of un-
known significance. She received yearly diagnostic mammograms for surveillance which 
showed only benign disease for 12 years. Then in the 13th year, the patient developed a pal-
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pable left breast mass at the mastectomy and radiation site. Ultrasound-guided biopsy was 
performed, and the pathology showed low-grade angiosarcoma with interanastomosing 
vascular channels, nuclear atypia, and hyperchromasia (Fig. 1b). The patient then underwent 
radical excision of the left breast and left chest wall angiosarcoma. As of the time of submis-
sion, the patient’s follow-up computed tomography scans have shown no evidence of recur-
rent disease.  
Discussion 
Angiosarcoma following the treatment of breast cancer was first described more than 
50 years ago in 1948 as a surgical complication from radical mastectomy and axillary lymph 
node dissection [3]. More recently, radiotherapy has been found to be a significant risk fac-
tor associated with secondary soft tissue sarcomas and in particular angiosarcoma [1, 2]. Not 
only is RAS of the breast rare, but it remains a challenge to diagnose and treat [1, 2]. Mery et 
al. [6] reviewed the National Cancer Institute Surveillance, Epidemiology and End Results 
(NCI SEER) database of early-stage breast cancer patients (approx. 560,000 cases) with up 
to 15-year follow-up data and estimated that RAS of the breast occurred in 0.9 out of 1,000 
cases. Furthermore, they estimated that adjuvant radiotherapy increased the risk of RAS of 
the breast by 9-fold compared to those who had received no radiation therapy [6]. It was 
also found that RAS of the breast has a poor prognosis with an overall 5-year survival of  
38% [6]. 
Multiple case reports describe the first signs of RAS of the breast as skin changes includ-
ing discoloration, dimpling, and thickening [2, 7]. In our first case, the patient presented with 
multiple red papules; however, in the second case, the presenting sign was a palpable breast 
mass which is unusual in the setting of RAS of the breast. RAS of the breast can be difficult to 
find on mammogram and may only appear as skin thickening. Rarely, angiosarcoma appears 
as an ill-defined or lobulated mass without calcifications [2]. The lack of radiographic find-
ings was seen with our second patient who had routine yearly mammograms which demon-
strated only benign findings. All patients with breast cancer, particularly those who have 
undergone radiation therapy, require routine follow-up as local recurrence rates can be 
high. The risk of radiation-induced angiosarcoma is highest 10 years after treatment and 
remains high for the following 10 years [8]. The prognosis of radiation-induced angiosar-
coma is poor and correlates with the time of onset, the age of the patient, and depth of tumor 
invasion. However, tumor grade is not a prognostic indicator [9, 10]. 
Treatment for radiation-induced angiosarcoma primarily involves an aggressive surgi-
cal approach as this represents the only potential for a cure [10]. In a study which looked at 
33 patients, Morgan et al. [5] found that even a standard mastectomy may be inadequate for 
treatment. They found that complete resection of all radiated tissue as opposed to resection 
of only the tumor provided a better prognosis and decreased the incidence of recurrence. 
Additional radiation therapy has been shown to provide little benefit as most radiation-
induced angiosarcomas are resistant to any additional radiation therapy [11]. Unfortunately, 
chemotherapy with anthracyclines/taxanes or surgery has been found to be only minimally 
effective in angiosarcomas with a reported response rate ranging from 17 to 34% [12, 13].  
Another approach currently being investigated is the use of molecularly targeted agents 
such as VEGF inhibitors. It has been suggested that since angiosarcomas overexpress VEGF 
at high levels, the use of VEGF inhibitors may be another effective strategy [14, 15]. Agulnik 
et al. [15] conducted a phase II study of 30 patients to study the efficacy of the VEGF inhibi-
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tor bevacizumab for the treatment of metastatic or locally advanced angiosarcoma and epi-
thelioid hemangioendothelioma. They found that 17% of the patients (2 angiosarcoma and 2 
epithelioid hemangioendothelioma) had a partial response with 50% of the patients (11 
angiosarcoma and 4 epithelioid hemangioendothelioma) showing stable disease with a 
mean time to progression of 26 weeks [15]. These findings are encouraging and there are 
several ongoing clinical trials investigating the use of combination therapy with a VEGF in-
hibitor and other chemotherapy agents (NCT02979899, NCT01462630, NCT02048722).  
In conclusion, radiation-induced angiosarcoma is a rare and aggressive disease which 
presents a potential challenge to the treating physician. Diagnosis can be challenging as it is 
often missed on mammography and often presents with dermatologic findings. Our patient’s 
presentation with a palpable breast mass represents a unique and potentially challenging 
presentation of radiation-induced angiosarcoma of the breast. Although RAS of the breast 
can be potentially life-threatening, studies have shown that the overall risk of angiosarcoma 
following radiation therapy does not outweigh the benefits of radiation therapy in the 
treatment of primary breast cancer [8, 10]. Ongoing clinical trials using combinations of 
VEGF inhibitors and chemotherapy may provide future avenues of treatment for this diffi-
cult-to-treat disease. 
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Fig. 1. Radiation-associated angiosarcoma of the breast. a Case 1 (H&E stain). Low-grade angiosarcoma 
surrounding an area of perineural invasion with small variable endothelial cells of mild atypia and hyper-
chromasia. b Case 2 (H&E stain). Vascular spaces are lined by enlarged and hyperchromatic endothelial 
cells. Specimen is absent of necrotic or mitotic cells, which is consistent with low-grade angiosarcoma. 
 
